THORNHILL, ON, Oct. 24, 2016 /CNW/ - Galderma, a global leader focused on medical solutions in skin health, is proud to celebrate the 20th global anniversary of the Restylane portfolio of products. Launched in Europe in 1996, Restylane is one of the world's most studied wrinkle fillers and has been administered in over 28 million treatments in 90 countries.1

"Introduced to Canada in 2000, Restylane was the world's first stabilized non-animal hyaluronic acid dermal filler, changing the aesthetic treatment landscape and shifting how people approach facial aging," says Wendy Adams, General Manager, Galderma Canada Inc. "This landmark anniversary not only marks the milestone of 20 years of standard-setting technology, but the empowerment of women and men who want to age on their own terms with safe, natural-looking, long-lasting results."

Supported by over 150 clinical studies on more than 3,000 subjects, Restylane is proven to have high treatment longevity and efficacy. It has grown to become one of the most trusted brands for natural-looking results, with a record of high patient satisfaction and safety.1

Restylane portfolio now the broadest range of dermal fillers

As part of its worldwide 20th anniversary celebrations of Restylane, Galderma is pleased to announce the further extension of the brand's portfolio with the integration of the Emervel Collection of hyaluronic acid fillers into the Restylane family. To be unveiled in the fall of 2016, the new broad range of HA dermal fillers will enable healthcare professionals to easily select the right products to meet the varied and specific needs of each patient under one trusted brand.

"A true test for any product is longevity. After 20 successful years in a field that is highly competitive, Restylane not only continues to be the "go to product," but provides a solid foundation for its expanding product line. This continued commitment to research and development as well as physician support through advanced product offerings is paramount for any successful practice to grow," says Dr. Andreas Nikolis, plastic surgeon and Senior Medical Director of the Victoria Park Clinical Research Centre, in Montreal.

"By integrating Emervel into the Restylane portfolio of products, we are pleased to offer clinicians an even wider variety of choices to tailor facial rejuvenation and achieve natural-looking, long-lasting results for each patient - whether it's filling lines and wrinkles, restoring volume to enhance a patient's overall appearance, or contouring and shaping to create facial harmony and balance," says Mike Charbonneau, Business Unit Director, Aesthetic & Corrective, Galderma Canada Inc.

For more information about the Restylane family of products, visit www.restylane.ca.

About Galderma

Dating back to 1961, Galderma is now present in 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin and hair. For more information, visit www.galderma.ca